Sharp Center for Research

Monday, May 20, 2019, 12:00 PM – 5:00 PM, Copley Conf Rms A-D, San Diego, CA Overview Sharp investigators will present their exciting research in a showcase format as part of Sharp’s inaugural participation in 2019’s Clinical Trials Day celebration! The showcase will include displays from Sharp research sites, Sharp research vendors, partners, CROs, pharmaceutical […]

Read More

Catalent Collaborates with MGB Biopharma to Provide Accelerated Formulation and Supply Services for Phase 2 Clinical Trial Materials

Catalent Collaborates with MGB Biopharma to Provide Accelerated Formulation and Supply Services for Phase 2 Clinical Trial Materials SOMERSET, N.J. – April 25, 2019 — Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it welcomed the commencement of Phase 2 clinical […]

Read More

Catalent Invests $14 Million at its Eberbach, Germany Softgel Facility

Catalent Invests $14 Million at its Eberbach, Germany Softgel Facility Expands Production and Packaging Capabilities, and Infrastructure in Response to Increasing Demand for Integrated Turnkey Services SOMERSET, N.J. – April 23, 2019 — Catalent, the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced […]

Read More

Catalent Celebrates Opening of Second Shanghai Facility to Optimize Global and Local Clinical Supply Solutions for China

Catalent Celebrates Opening of Second Shanghai Facility to Optimize Global and Local Clinical Supply Solutions for China SOMERSET, N.J. – April 11, 2019 — Catalent Pharma Solutions, a global leader in clinical supply services, today announced the completion of its new, 30,000-square-foot clinical supply facility in Shanghai, China. The event was marked with an official […]

Read More

Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion

Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion Will provide new expertise and capabilities in one of the fastest-growing areas of healthcare, positioning Catalent for accelerated long-term growth SOMERSET, N.J. and BALTIMORE, Md. – April 15, 2019 – Catalent, Inc. (NYSE: CTLT), the leading global diversified provider of advanced delivery technologies […]

Read More

Catalent Expands OptiMelt® Hot Melt Extrusion Capabilities at Somerset Drug Development Center of Excellence

Catalent Expands OptiMelt® Hot Melt Extrusion Capabilities at Somerset Drug Development Center of Excellence SOMERSET, N.J. – April 4, 2019 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has invested a further $5 million at the company’s […]

Read More

Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma Next Generation Antibody-Drug Conjugate Developed Using Catalent’s SMARTag® ADC Technology

Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma Next Generation Antibody-Drug Conjugate Developed Using Catalent’s SMARTag® ADC Technology Toronto, Ontario, and Somerset, N.J. – April 1, 2019 – Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, and Catalent, the leading global provider […]

Read More